Intensified Biomanufacturing with up to 4x titers

Explore a unique, intensified, fed-batch process for producing monoclonal antibodies in mammalian cell culture at a yield of three to four times the normal rate using other methods.

Discover more details about global CRO/CDMO Syngene’s media-blending strategy, with an inside look at the process and its benefits.

Read now to learn more about how Syngene is:

• Increasing yield without increasing the existing manufacturing footprint
• Using highs seeding density to accelerate protein production and boost upstream productivity
• Minimizing waste and maintaining cell health
• Working more efficiently to shorten production times and reduce costs
• Producing antibodies of consistent quality while achieving higher titers of 7-12 g/L